The Business of Biofabrication

In a new development for bioprinting, CollPlant Biotechnologies and Stratasys Ltd. have launched a pre-clinical study focused on the viability of 3D-printed, regenerative breast implants. This collaboration marks a significant stride in the $3 billion breast implant market, introducing a novel approach that could redefine both reconstructive and aesthetic procedures.

The Innovation Behind the Implants

The implants, designed with CollPlant’s proprietary rhCollagen-based bioinks, are produced using Stratasys’ advanced Origin® 3D printer. The 200cc implants aim to regenerate natural breast tissue, offering a promising alternative to traditional silicone implants. The key feature of these implants is their ability to gradually degrade as they are replaced by the patient’s own tissue, potentially eliminating the long-term complications associated with synthetic implants.

A Collaborative Effort in Bioprinting

It’s interesting because before 2023 CollPlant was working with 3D Systems to develop breast implants. After 3D Systems ended the collaboration, Stratasys saw the opportunity and began working with CollPlant, both Israeli based companies to optimize the printing process for these regenerative implants. The Stratasys Origin printer (below) has been specifically adapted to handle the unique requirements of CollPlant’s bioinks, ensuring that the implants meet high standards of resolution and physical integrity. Initial results from the ongoing pre-clinical study are expected in the first half of 2025.

“We’re thrilled with the progress made in developing these revolutionary breast implants,” said Yehiel Tal, CEO of CollPlant. “By combining CollPlant’s bioprinting expertise with Stratasys’ technological innovations, we’re moving closer to offering patients a safer and more natural alternative to current breast augmentation methods.”

3D printed breast implant consisting of 200cc in volume of CollPlant’s rhCollagen-based bioinks produced on a Stratasys’ Origin® printer. (Photo: Business Wire)

Addressing a Growing Market Need

The global breast implant market is currently valued at approximately $3 billion, with breast reconstruction and augmentation procedures being the second most common plastic surgeries performed worldwide. Traditional methods rely on silicone implants or autologous fat transfer, both of which come with significant risks and limitations. CollPlant’s regenerative implants could address these issues by promoting tissue regeneration while avoiding the complications associated with synthetic materials.

Recent pre-clinical studies by CollPlant have already demonstrated promising results, including the development of well-vascularized connective tissue within the implants and early signs of biodegradation. These findings bolster confidence in the safety and effectiveness of the implants, paving the way for future clinical trials.

What to watch?

CollPlant and Stratasys are in the running to offer a competitive novel breast implant. As the pre-clinical study progresses, its important to watch and listen to the results of what comes from those studies.

For more on bioprinting breast implants check out this perspective.

Stay tuned to Business of Bioprinting for updates on this and other advancements in the intersection of bioprinting and healthcare.

About Stratasys

Stratasys Ltd. is a global leader in additive manufacturing, pioneering the use of advanced 3D printing solutions across diverse industries, including healthcare, aerospace, automotive, consumer products, and fashion. With a portfolio that includes smart and connected 3D printers, high-performance polymer materials, and an integrated software ecosystem, Stratasys is at the forefront of transforming traditional manufacturing processes. The company’s innovations empower organizations to enhance product design, streamline manufacturing, and improve supply chain agility, ultimately delivering competitive advantages. Headquartered in Eden Prairie, Minnesota/Rehovot, Israel Stratasys continues to push the boundaries of what’s possible in 3D printing, driving the industry forward and creating new opportunities for customization and efficiency.

About CollPlant

CollPlant Biotechnologies is a regenerative and aesthetic medicine company that leverages cutting-edge bioprinting technology to create innovative solutions for tissue repair, organ manufacturing, and medical aesthetics. The company’s flagship technology is based on recombinant human collagen (rhCollagen) produced through proprietary plant-based genetic engineering. This breakthrough enables CollPlant to develop products that closely mimic human tissue, offering groundbreaking advancements in areas such as 3D bioprinting of tissues and organs. Headquartered in Rehovot, Israel, CollPlant is dedicated to transforming the future of medicine by providing safer, more effective alternatives to traditional treatments. Through strategic partnerships and continuous innovation, CollPlant is setting new standards in the field of regenerative medicine.

Forward Looking Statement

The views and opinions expressed are based on current information available and are subject to change. This site contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from those expressed or implied by such forward-looking statements. Readers are encouraged to do their own research and consult with a qualified financial advisor before making any investment decisions. The author does not assume any liability for losses incurred by readers.